^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Solid Tumor
    Drug:TNG260 (RCOR1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

    Excerpt:
    ...- All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method...
    Trial ID:
    NCT05887492
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2022
    Title:

    444 TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11

    Published date:
    11/08/2022
    Excerpt:
    Treatment of an α-PD1 resistant STK11-mutant MC38 syngeneic tumor model with TNG260 re-sensitizes this model to treatment with α-PD1. The combination of TNG260 and α-PD1 led to durable complete tumor regressions in the majority of treated animals.
    Secondary therapy:
    PD1 inhibitor
    DOI:
    10.1136/jitc-2022-SITC2022.0444